The groundbreaking rise of Sildenafil presented a significant prospect for investors , but its period has lapsed , creating a challenging landscape. Alternative versions have appeared in the arena, eroding profits and putting a squeeze on profit margins . While established healthcare companies hold a foothold in this field , the outlook seems get m